1. Home
  2. Live Updates
  3. Newly diagnosed multiple myeloma

Live Breaking News & Updates on Newly diagnosed multiple myeloma

Stay informed with the latest breaking news from Newly diagnosed multiple myeloma on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Newly diagnosed multiple myeloma and stay connected to the pulse of your community

Patients With NDMM Who Fail QUAD Treatment Within 18 Months Show Poor Response to Subsequent Treatments

The investigators note that patients with newly diagnosed multiple melanoma who receive quadruplet treatment have unmet needs that must be further examined in future research.

United-kingdom , British , Key-takeaways , Newly-diagnosed-multiple-myeloma , Stem-cell-transplantation , Treatment-failure-duration , Progression-free-survival , Future-directions , British-journal ,

Data From 2023 ASH Annual Meeting Provide Positive Updates in Multiple Myeloma

Experts discuss treatment in newly diagnosed multiple myeloma and the role of CAR T-cell therapies and bispecifics in relapsed/refractory disease.

California , United-states , Illinois , San-diego , Chicago , American , Caitlin-costello , Krinak-patel , American-society-of-clinical-oncology-annual-meeting , Onclive-peer-exchange , American-society-of-hematology-annual-meeting-exposition , American-society

Considerations for Combination Therapy and MRD Testing in Newly Diagnosed Multiple Myeloma Patients

A medical expert navigates the treatment landscape for patients newly diagnosed with multiple myeloma.

Conference-perspectives , Multiple-myeloma , Combination-therapy , Newly-diagnosed-multiple-myeloma , American-society-of-hematology , Ash , Triplet-therapy , Quadruplet-therapy , Perseus-trial , Daratumumab , Bortezomib

ASH 2023: Analyzing IsKia Trial

The IsKia trial findings presented at ASH 2023 are highlighted by Dr Fonseca.

Conference-perspectives , Multiple-myeloma , Analyzing-iskia , American-society-of-hematology , Ash , Newly-diagnosed-multiple-myeloma , Triplet-therapy , Quadruplet-therapy , Perseus-trial , Daratumumab , Bortezomib

Examining Data from MonumenTAL-2 Study

The MonumenTAL-2 study is discussed by Rafael Fonesca, MD.

Conference-perspectives , Multiple-myeloma , American-society-of-hematology , Ash , Newly-diagnosed-multiple-myeloma , Triplet-therapy , Quadruplet-therapy , Perseus-trial , Daratumumab , Bortezomib , Lenalidomide

The Evolving Treatment Paradigm for Transplant Ineligible MM

The expert panel discusses how the standard of care for transplant-ineligible NDMM has evolved and reviews recent updates in this space.

Multiple-myeloma , Evolving-treatment-paradigm , Transplant-ineligible , Mm , Newly-diagnosed-multiple-myeloma , Ndmm , Mm-treatment , Transplant-eligible , Daratumumab , Lenalidomide , Dexamethasone

Highlights from ASH 2023 in Transplant-Eligible NDMM

Experts in multiple myeloma discuss highlights from the ASH 2023 meeting around transplant-eligible NDMM with particular focus on the PERSEUS and GRIFFIN trials and the clinical implications of the results of these studies.

Multiple-myeloma , Mm , Newly-diagnosed-multiple-myeloma , Ndmm , Mm-treatment , Transplant-eligible , Perseus , Griffin-trial , Perseus-trial , Daratumumab , Lenalidomide

Advances in the Treatment of High-Risk MM

Clinical insights on the definition of high-risk multiple myeloma and the treatment of patients with high risk disease, including how the results from the IsKia trial might impact practice.

Multiple-myeloma , Mm , Newly-diagnosed-multiple-myeloma , Ndmm , Mm-treatment , Transplant-eligible , High-risk , Standard-risk , Iskia , Isatuximab , Carfilzomib

Role of Transplant and MRD in Newly Diagnosed MM

Amrita Krishnan, MD, and Saad Z. Usmani, MD, MBA, FACP, offer their perspectives on the role of stem cell transplant and MRD testing in patients with newly diagnosed multiple myeloma.

Saadz-usmani , Multiple-myeloma , Newly-diagnosed , Mm , Newly-diagnosed-multiple-myeloma , Ndmm , Mm-treatment , Transplant-eligible , High-risk , Standard-risk , Quadruplet

Results of the Phase III Randomized IsKia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone as Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients

Francesca Gay, MD, PhD, presents results from the phase III randomized IsKia trial investigating isatuximab-carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in patients with newly diagnosed multiple myeloma.

California , United-states , San-diego , Iskia-trial , Pre-transplant-induction , Post-transplant-consolidation , Newly-diagnosed-multiple-myeloma , Multiple-myeloma , Iskia , Iskia-study , Isatuximab